Nestlé expands distribution of CBD products formulated by VESIsorb in Europe
The agri-food giants are entering the CBD game. The first large-scale CBD production was completed and delivered earlier this month using only European resources, from cultivation and extraction of hemp biomass in Slovenia to drug delivery technology and to the production of capsules in Switzerland. Geocann and Nestlé have announced the European launch of gel formulations made from a broad spectrum hemp extract using the patented drug delivery system VESIsorb®. The company takes advantage of a study on CBD published by the journal Molecules and Geocann's product safety data to build momentum.
“We are extremely proud to expand our relationship with Nestlé brands for healthcare professionals in Europe following their success in the US market last year,” said Jesse Lopez, CEO and Founder of Geocann. "The validation by their management team of science backed and clinically proven hemp products is a milestone for our industry and brings exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb."
The VESIsorb system
VESIsorb is a naturally self-assembling colloidal droplet delivery system. Publication in the specialist journal Molecules published the results of a double-blind crossover study comparing the pharmacokinetic (PK) parameters of a broad spectrum hemp extract formulated with VESIsorb to those of the same broad spectrum hemp extract combined with medium chain triglyceride oil (MCT).
Overall, the VESIsorb formulation showed statistically significant improvements for all pharmacokinetic parameters measured, including peak plasma CBD concentration (Cmax), area under the curve (AUC), and time to peak d. absorption (Tmax). The full manuscript can be viewed on the Geocann website.https://nutraceuticalbusinessreview.com/news/article_page/Nestle_expands_distribution_of_VESIsorb_formulated_CBD_products/169720
Dr Barry Ritz, Scientific Director of Pure Encapsulations, said “With Geocann, we share a passion and commitment to product safety, purity and performance. Our partnership is founded on a relentless effort to ensure that these products are the most scientifically supported CBD products in the world, thus setting the benchmark for consumer expectations and healthcare professional demands ”.
According to Lopez, CEO and founder of Geocann, in addition to recent pharmacokinetic studies and stability data for its products, further investments in clinical research focused on pharmacokinetic performance and clinical endpoints are underway. In addition, numerous toxicological studies have been carried out and will be published this year as part of the GRAS (Generally Regarded As Safe) notification from the FDA and Geocann's request for novel food status.